Secondary outcomes were modification of laboratory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); SpA disease activity measured by composite index ankylosing spondylitis disease activity score (ASDAS) and bath ankylosing spondylitis disease activity index (BASDAI); patient reported outcomes pain-visual analogue scale (VAS) and patient global assessment (Pt-GA); disability evaluated by health assessment questionnaire (HAQ); safety of golimumab. The gene discussed is CRP; the disease is ankylosing spondylitis.